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Abstract 
Vaginal meshes used in the treatment of stress urinary incontinence (SUI) and pelvic organ 
prolapse (POP) have produced highly variable outcomes causing life-changing complications 
in some patients while providing others with effective, minimally invasive treatments. The 
issue surrounding the risk:benefit ratio when using the vaginal meshes  is complex in which a 
combination of several factors, including the inherent incompatibility of the mesh material 
with some applications in pelvic reconstructive surgeries and the lack of appropriate 
regulatory approval processes at the time of premarket clearance of these products  , have 
contributed to occurrence of complications caused by vaginal mesh. Surgical mesh used in 
hernia repair has evolved over many years from metal implants to knitted polymer meshes 
that were adopted for use in the pelvic floor for treatment of POP and SUI. The evolution of 
the material and textile properties of the surgical mesh was guided by clinical feedback from 
hernia repair procedures, which were also being modified to obtain the best outcomes with 
use of the mesh. Current evidence shows how surgical mesh fails biomechanically when 
used in pelvic floor and materials with improved performance can be developed using 
modern material processing and tissue engineering techniques.  
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[H1] Introduction 
Vaginal meshes that are currently used in the surgical treatment of stress urinary 
incontinence (SUI) and pelvic organ prolapse (POP) can result in life-changing complications 
in some women who have vaginal mesh implants 1. These adverse outcomes are now 
considered a major public health problem; New Zealand becoming the first country in the 
world to ban the use of transvaginal POP mesh products while still allowing transvaginal SUI 
meshes (except minislings) in December 2017 2. In the UK, two public enquiries performed 
by the Scottish (in 2015)3 and English (in 2017) 4 governments, in part, as a result of pressure 
from patient groups led to suspension of vaginal mesh products, both for SUI and POP, from 
July 2018 onwards 5. The newest guidance by the National Institute of Health and Care 
Excellence (NICE) in the UK recommends that retropubic sling materials can be offered to 
women with SUI if nonsurgical management has failed 6. In response, the British Society of 
Urogynaecologists expressed strong disagreement with the decision to suspend the use of 
vaginal mesh for SUI, but not POP, stating that this decision would deprive many women of 
an effective and safe treatment option as demonstrated by level I evidence 7 8. Mesh 
manufacturers are currently facing lawsuits in the USA and Europe 9. The issue with mesh 
repairs for SUI and POP is complex, as the vaginal mesh is implanted in the female pelvic 
floor in several different ways with very different outcomes in efficacy and complication 
outcomes. When used as a tape to treat SUI, many patients are effectively cured with the 
benefits outweighing the risks 10,11, whereas when used for transvaginal POP repair, 
complications are more frequent 12 with no obvious improvement in patient outcomes in 
terms effectiveness and quality of life compared with native tissue repairs 13. In complex 
circumstances such as are apparent with the use of mesh,going back to basics and revisiting 
how the problem began might help clarify the whole picture.  
 Surgical mesh material was initially designed and used for hernia repair 14. The clinical need 
for prosthetic materials to replace the defective abdominal wall fascia was recognized in the 
17th century. Theodor Billroth, an eminent general surgeon at the time said  “/ĨǁĞĐŽƵůĚ
artificially produce tissues of the density and toughness of fascia the secret of the radical 
ĐƵƌĞŽĨŚĞƌŶŝĂǁŽƵůĚďĞĚŝƐĐŽǀĞƌĞĚ ”15. Since then, many materials and several different 
surgical techniques have been used. The search for an ideal hernia mesh still continues 16; 
however, the polypropylene (PPL) meshes are widely accepted as the standard mesh 
materials 17. .  
Following their success in hernia repair surgeries, PPL meshes started to be used in the 
female pelvic floor, firstly to treat SUI in 1970s. The initial trials did not lead to widespread 
clinical use of these meshes for SUI until Ulmsten and Petros popularized the midurethral 
sling surgeries in early 1990s. .  The medical device regulations at the time permitted the 
widespread clinical use of PPL mesh without requiring evidence from clinical trials to 
demonstrate their safety and efficacy for these particular new applications in the pelvic 
floor. The thinking seems to have been that if these mesh implants worked well in one site of 
the body they would work equally well in another site. This assumption can now be 
considered naive, as we know today that the anatomical, biological and mechanical 
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requirements of the female pelvic floor are considerably  different from those of the 
abdominal wall. Briefly, the design requirements for a vaginal mesh to support the pelvic 
organs and to be inserted through the vagina are different from those needed for an 
abdominal hernia repair mesh. 
In this Perspective, we explore how PPL mesh has evolved as a material used in abdominal 
hernia repair and how it was translated for use in female pelvic floor. We review the basis 
for using the mesh for treatment of SUI and POP to elucidate the targets of surgical 
treatment and how suitable the mesh is to replace the defined target. We describe the 
material properties of mesh as it relates to occurrence of mesh complications. Finally, we 
discuss current approaches to developing new materials using a range of nondegradable and 
degradable materials and tissue engineering techniques.  
 
 
5 
 
 
[H1] The evolution of surgical mesh  
 
 
[H2] Mesh used for abdominal hernia repair 
Ventral hernias occur owing to a defect in the fascia covering abdominal muscles and 
surgical treatments aim to repair this structural defect. Prosthetic materials are mainly 
needed to fill in large tissue defects that cannot be closed with primary suture repairs or to 
reduce the chances of recurrence after primary repairs. The first prosthetic material used in 
hernia repair in 1902 was made of silver 18  , followed by tantalum in 1940 19 (Figure 1) 
Tantalum wire mesh became quite popular at that time owing to its inertness and 
antimicrobial properties 20. However, metals are inherently unsuitable for soft tissue repairs 
such as hernia repairs, as they are stiff and can fragment 21. After the plastics revolution in 
the early 20th century materials made of nylon (polyamide) and Dacron (polyester, also 
known as polyethylene terephthalate) started to be used 22. Although these plastic meshes 
offered substantial advantages over metallic meshes owing to their ductility (the ability of a 
material to undergo plastic deformation without cracking or failure) and strength, their 
initial design was poor, with small pores and multifilament structure.  
It was only after Usher, a hernia surgeon, optimized both the material and textile properties  
of plastic mesh (Marlex) that acceptance became widespread14. He used a high-density 
polyethylene and a new manufacturing method to extrude it as a monofilament 14. He 
optimized the textile properties such as  porosity, stretchability and tensile strength  of the 
new mesh to enable fibroplasia while keeping the necessary tensile strength. In 1962, an 
improved version of Marlex mesh made of PPL was introduced. PPL had improved material 
and textile properties (such as high tensile strength and good flexibility) and increased heat 
resistance compared with polyethylene, enabling effective sterilization without 
compromising the material properties 23. PPL became the standard material for modern 
surgical mesh over the next couple of decades  17. The initial PPL design remained largely 
unchanged over the next 50 years, but modifications to the textile properties of the mesh 
were continuously made to improve clinical outcomes. A relationship between the physical 
properties (pore size, fibre diameter) of the material and material related complications had 
become a well- defined phenomenon by 1997 which is crystalized by the Amid classification 
of the surgical meshes 24. Basically, light-weight meshes reduced inflammation, foreign body 
reaction, fibrosis 25,26, chronic pain and abdominal stiffness in clinical studies 27. Also light-
weight meshes with large pores  had increased flexibility compared to heavy- weight meshes 
and were similarly elastic to the abdominal wall 28. As a result, the initial heavy-weight 
meshes with small pores  ?A? ? ?A?ŵ ?(such as Marlex) were replaced with lighter-weight 
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meshes with larger pores. Nevertheless, the heavy-weight mesh can still be necessary for 
selected hernia repairs in which maximum mechanical stability is desired 29.  
Thus, mesh for surgical repair has evolved from a metal wire through plastic fabrics to the 
current PPL mesh that has a range of bulk densities and pore sizes (Fig 1). This evolution and 
refinement of mesh composition was conducted on the basis of clinical feedback over a 
considerable period of time and the process is probably ongoing.  
[H2] Surgical technique for abdominal mesh use  
 In parallel to the modifications made to the textile properties of mesh, surgeons also 
modified the way they use the new plastic prosthesis when treating hernia. Many different 
surgical approaches and operative techniques have been described in the literature 
concerning hernia repair 30. Development of some of these techniques seems to have been 
driven by the availability of the plastic mesh and efforts to make use of its material 
properties. For example, mesh plug surgeries for inguinal hernia repair were introduced 
making use of the flexibility and fibrosis-inducing properties of plastic meshes 20  The 
concept of creating an inflammatory reaction at the site of the hernia to stimulate fibrous 
tissue formation was previously known, but this reaction could only be achieved using 
caustic substances or wooden plugs before plastic mesh was introduced 31. Another example 
of how surgeons developed surgical technique to use plastic mesh is incisional hernia repair. 
The first technique used for repair of midline incisional hernia using plastic mesh was the 
inlay technique in which the mesh is inserted in between the edges of the fascia defect to fill 
the gap (Figure 2). The inlay positioning was, unfortunately, associated with high recurrence 
rates. In a pooled analysis, inlay mesh placement had a recurrence rate of 30.2% compared 
to 16.5% and 7.0% for onlay and sublay placements, respectively 32. The next development 
or surgery for this repair was the onlay technique, in which mesh is placed on top of the 
repaired fascia defect in a tension-free manner (Fig. 2) . Onlay repairs involve extensive 
subcutaneous tissue dissection and a large area of the mesh implant stayed very close to 
skin, increasing the chances of wound complications such as infection and seroma formation 
33. To reduce complications a sublay (retrorectus) technique was then developed, in which 
the mesh is put underneath thick muscle tissue (retrorectus, Fig. 2); specifically, the mesh is 
placed under the rectus muscle and over the posterior sheath of the rectus muscle (above 
the linea semilunaris). Below the semilunar line, the mesh is placed underneath the rectus 
muscle and just over the preperitoneal fat. It appears that the sublay technique  is now 
considered the gold-standard technique for incisional hernia repair, particularly in wound 
beds that are difficult to treat (for example, poorly vascularized or wounds that have been 
repeatedly operated on) 32,34. Thus, the position of the mesh in relation to the tissue layers 
to be repaired seems to be a factor that is relevant to mesh-related complications in hernia 
repair surgeries 35. Taking altogether, it appears that some surgical techniques in hernia 
repair surgeries have been driven by the availability of new materials that than went through 
a process of further refinement over years until the technique was optimized in the 
particular clinical context.   
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Just as new materials necessitated new surgical approaches, developments in surgical 
technologies also required modifications in material properties for hernia surgery. 
Widespread use of laparoscopy led to the development of an underlay repair technique, that 
can be performed in the introcorporeal environment by placing the mesh on the inside 
surface of the abdominal wall in direct contact with intra-abdominal organs  (Fig. 2). The 
mesh in these cases needed to have additional antiadhesive properties to prevent adhesion 
of intra-abdominal organs, achieved by using materials with this characteristic (such as 
Teflon-based materials) to fabricate or coat the mesh  28. The success rates of laparoscopic 
mesh repair surgeries appear to be similar to open hernia repairs with lower incidence of 
wound complications and higher incidence of bowel obstruction in laparoscopic technique 
36,37.  
In conclusion, the use of synthetic mesh has revolutionized hernia repair surgeries 38. 
Retrospectively, the material and the surgical technique seem to have developed 
concurrently over >50 years to obtain good surgical outcomes for hernia repairs.  
  
[H2] Meshes in pelvic floor surgery 
The first prosthetic material used in pelvic floor surgery, in a 1947 case series, was a 
tantalum plate implanted transvaginally to treat SUI 39. The underlying theory was to induce 
fibrosis and form a fixed plane at the posterior part of the proximal urethra 39. The same 
material  was then implanted transvaginally to treat cystoceles in an effort to reduce 
recurrence after surgery 40. Exposure of the tantalum mesh was reported in 4 out of 10 
patients within 6 ?18 months indicating that tantalum is not suitable for use in the pelvic 
floor39. 
The first nonmetallic prosthetic material used for pelvic floor surgery, in 1968, was a gauze 
hammock made of polyethylene (Mersilene) that was used as a sling to treat SUI 41. This 
hammock was placed at the bladder neck in a tensionless manner and the edges were fixed 
to the rectus fascia. A success rate of >80% was reported in 71 patients at up to 5 years 
follow-up monitoring 41. Although no long-term follow up data was ever presented, tissue 
damage with dense scarring was reported in the early postoperative period 41. Two years 
later, polyethylene was replaced with PPL (Marlex) mesh 42, which was considered inert and 
resistant to infection. This mesh was used to treat SUI in a modified gauze hammock 
operation in 20 patients in which mesh is placed at the bladder neck and attached to the 
Cooper ligament. A 5% erosion rate was reported with most of 281 patients  followed for 5 
years 43. This erosion rate could be the reason why these operations have not gained 
widespread acceptance. The chronology of events shows that materials were adopted for 
use in the pelvic floor after they were first used in hernia surgeries (Figure 1). 
Widespread use of the surgical mesh in the pelvic floor started after 1995 when Ulmsten and 
Petros first described intravaginal slingoplasty 44. In these operations, a mesh sling made of 
8 
 
PPL was applied with its own introducer (tunnelling device) as day-case procedures, , 
forming the basis of the modern midurethral tape procedures (Figure 3c) 45. The first 
intravaginal synthetic sling material received clearance from the FDA in 1996 was ProteGen, 
which is a polyester mesh coated in bovine collagen 46. Notably, this product was recalled 3 
years after it was cleared owing to severe complications such as erosion, infection and pain 
47. Despite this experience, ProteGen was used as a predicate device and the TVT of Ethicon 
made of PPL was approved by the FDA in 1999 48 which then generated the forward chain 
together with many others 46. The transvaginal mesh devices for POP repair were also 
approved on the basis of their equivalence to ProteGen as the predicate device46.  
The first prosthetic materials used in pelvic floor reconstruction were reproductions of 
hernia meshes, such as Gyneacare®. Subsequently, mesh kit devices such as Perigee and 
Apogee were manufactured and the first mesh kit device was approved by the FDA in 2004 . 
Efforts were then made to adjust the textile properties, such as weave pattern and 
geometry, of the mesh specifically for urogyneacological applications. Studies on mesh 
geometry and its relationship with pore stability under mechanical distension led to the 
introduction of new mesh materials that were designed specifically for applications in the 
pelvic floor, such as DynaMesh 49; however, to the extent of the effect on reducing mesh-
related complications is unclear.  
[H1] PPL mesh as a material 
PPL ([C3H6]n) is a thermoplastic polymer (meaning it can be processed and reprocessed 
when heated) that is synthesized from propylene monomers by addition polymerization 50. 
After the raw material of PPL is synthesized, it is melted and extruded into a continuous 
monofilament (rather than alternative processes, such as electrospinning; Fig 4. ). Different 
polymer processing technologies can lead to considerable differences in the final product 
and tissue response to it (Table 2) .The monofilament can then be woven or knitted 51. 
Knitted meshes are preferable to woven meshes for use in the pelvic floor  as they are more 
porous and flexible; furthermore, woven meshes are associated with an increased 
complication rate as the filaments of the woven mesh can slide together resulting in 
interfibre spaces that allow bacteria in but not immune cells 52. After knitting, the mesh is 
cleaned of the residual chemicals, cut into shape and sterilized by autoclaving or high-
pressure steam.  
As well as the raw material, additives are included in the polymer mixture to help the raw 
material  become suitable for industrial processing. Additives can also be used for property 
enhancement and to neutralize the effects of other additives. For example, the PPL needs to 
be thermally stabilized by additives to survive melt processing, antioxidants can be added to 
enhance material properties and  catalyst deactivators neutralize any remaining catalyst 
residues 53.  Although additives are used much less in medical-grade materials than in 
industrial plastics, not to compromise biologic compatibility of medical grade plastics, when  
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they can constitute up to 30% of their total polymer weight 54. Thus, the substance of 
finished mesh product constitutes the raw material and the additives.  
The device manufacturers rely on suppliers of raw materials and components to obtain 
polymer resins. They are required to implement supplier qualification procedures that 
include audits, incoming raw material and component specifications and quality metrics 55. 
These qualification processes have been the subject of an FDA statement 56 in which a 
change in supplier together with variability between the polymer resins from both suppliers 
were found; however, the difference did not raise any new safety and effectiveness 
concerns with no evidence of adverse clinical reports.  
Surgical meshes made of other raw materials, such as polyester, polytetrafluoroethylene 
(PTFE) and polyvinylidenfluoride (PVDF) have also been used clinically 20. Different polymers 
can be used for different purposes with distinct biological effects. For example, PTFE has 
antiadhesive properties making it preferable for intraperitoneal applications 57. However for 
the treatment of SUI, PTFE (Goretex®) was not considered an ideal material 45 as the initial 
reports showed mesh removal rates of up to 21% in 31 months after surgery 58. PPL was 
suggested to have two main advantages over polyester and PTFE meshes: PPL is better 
accepted by tissues owing to inherent material properties  and has strong adhesive 
properties that prevented sliding, removing the need for any fixation points during 
application, unlike PTFE for example. 44,59 PPL is the most commonly used material in all 
hernia surgeries. 
 
[H2] Outcomes of mesh for SUI and POP  
 When used as a tape to treat SUI  , mesh has a long-term subjective cure rate of up to 93% 
10. Serious mesh-related complications still occur in at least 4% of patients who had a mesh 
implant for SUI. 11. When used for POP repair, mesh can be implanted either transvaginally 
or transabdominally. The success of transabdominal repairs can be >90% 60, but the rates 
can change considerably depending on the definition of success 61. Mesh erosion still occurs 
in up to 6% of women who had abdominal sacrocolpopexy by 2 years after abdominal 
sacrocolpopexy 62 and 10% at the 7-year follow-up point 63 . However, when the same mesh 
is implanted via the vagina the results are very different. Transvaginal mesh implantations 
result in a decrease in awareness of prolapse, reduced recurrence of prolapse on physical 
examination and reduced rates of repeat surgery compared with native tissue repairs in the 
short term (1-3 years). However, these outcomes came at the expense of increased rates of 
repeat surgery for mesh complications or recurrent incontinence and/or prolapse in another 
vaginal compartment  64. The safety of using mesh for transvaginal POP repair procedures is 
now widely questioned as a mesh erosion rate of 8% in the 1 ?3 year follow-up period has 
been reported 64  and a rate of up to 42% was observed in a study that monitored patients 
for 7 years 12. Growing public concern about mesh complications contributed to the 
initiation of investigation of the use of mesh for POP and SUI in two public inquiries in the UK 
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in 20173,4. The Scottish Independent Review on the use, safety and efficacy of transvaginal 
mesh implants looked at the frequencies of midurethral sling surgeries, transvaginal mesh 
and transabdominal mesh insertions for POP and SUI  and compared them with nonmesh 
alternatives retrospectively between 1997 and 2016 3. For SUI repair, this review 
demonstrated that hospital admission rates for late complications and for further SUI 
surgeries within 5 years of the surgery with mesh slings was not different from 
colposuspension (the most commonly performed anti-incontinence operation not using the 
mesh). Fewer immediate postoperative complications occurred with mesh slings surgery 
than colposuspension . However, for transvaginal POP repair the use of mesh did not reduce 
the need for further surgery 3 and readmission rates within 5 years were higher with all 
transvaginal mesh implantations than with native tissue repairs. Similarly, the review of 
hospital episode statistics by NHS England did not show any difference in outpatient hospital 
admissions after vaginal mesh surgeries compared to native tissue repairs 3. However, it is 
worth noting that in this review surgery for prolapse was not sub- grouped into POP repair 
via transvaginal versus transabdominal approaches. Such a subgroup analysis may have led 
to different figures as we know transvaginal mesh surgeries are associated with more 
complications than transabdominal route.  A recent consensus document recommends that  
transvaginal mesh for POP should be reserved for selected patients and performed only in 
specialized centres 65. The number of mesh-augmented transvaginal POP repair procedures 
sharply declined from 27% of all POP repairs to 2%  after the FDA warning on the use 
transvaginal mesh products in 2011 66. A similar trend was observed in the use of 
transvaginal mesh for SUI: the review of hospital episode statistics by NHS England showed a 
48% reduction in mesh tape procedures performed in England between 2008 and 2017, with 
a sharper decline after 2013 4. Also, the data show a decrease in the number of midurethral 
sling (MUS) surgeries performed in academic centres and an increase in pubovaginal sling 
procedures 67. Taken altogether there appears to be a considerable reduction in use of 
vaginal mesh implants for treatment of SUI and POP while the number of native tissue 
repairs increase.  
[H2] Issues with medical device regulations  
Medical devices comprise a wide range of tools from gloves to sophisticated prosthetic 
devices. Accordingly, these devices are approved by regulatory bodies via a variety of 
different routes. Medical devices are classified by the FDA in the USA, and similarly by other 
regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) 
and European Medicines Agency (EMA), into three classes based on the level of control 
required to assure of their safety and efficacy 68. About two-thirds of devices (such as tongue 
depressors and gloves) are low risk (class I). Low-risk devices are subject to the least control 
and are exempt from premarket submission 69. The other approximately one-third of 
medical devices are moderate risk (class II, such as catheters and surgical sutures). Most 
class II devices are approved via a process called the 510k, in which proof that the device is 
substantially equivalent to previous legally marketed devices is enough for clearance 70. Only 
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1% of medical devices are classified as high risk (class lll, such as pacemakers and artificial 
urinary sphincters) and premarket approval is necessary for these devices. Premarket 
approval involves determination of safety and efficacy on the basis of results of clinical trials 
69.  
The vaginal meshes used in the treatment SUI and POP were cleared via the 510k route as 
being equivalent to hernia meshes and made available for widespread use, in the absence of 
clinical evidence of their safety and efficacy when used in pelvic floor surgery 46. A total of 61 
mesh products were cleared via the 510k route with claimed equivalence to ƚŚŝĐŽŶ ?Ɛ
Mersilene hernia mesh (approved in 1985) and the ProteGen sling (approved in 1996) 46. As 
no clinical trials were required before marketingmanufacturers did not monitor long-term 
adverse effects and the opportunity to refine and improve materials was largely neglected 
for at least a decade. Real-life data now show that the use of PPL mesh in urogyneacological 
surgery for SUI and POP can have life-changing consequences such as chronic pain, infection 
and organ perforation 71,72  for some women. Eventually in 2016, the FDA reclassified 
transvaginal mesh devices from being class II (moderate-risk device) to class III (high-risk 
device) requiring clinical data on efficacy and safety of these devices before clearance 73. As 
a result, some manufacturers removed the products from the market 74. As a result of 
lessons learnt from the vaginal mesh experience, new European regulations on medical 
devices entered into force on May 2017 that aim to establish a robust, transparent, 
predictable and sustainable regulatory framework for medical devices which ensures public 
safety while supporting innovation 75,76. . New definitions to refer medical devices have been 
introduced (such as active device, implantable device and single use device) and regulations 
for placing them on the market, tracing the supply chains and postmarket surveillance are 
now implicated force.  
 
[H1] The mechanics of mesh for SUI and POP 
[H2] Use of mesh for SUI 
In the past 100 years, surgical treatment of SUI has developed for three main purposes: 
restoration of normal retropubic position of the urethra (retropubic suspensions), 
strengthening of the external sphincter (transvaginal plications) and sling operations 77. Sling 
operations were the precursor for synthetic midurethral sling surgeries. The fascia sling 
surgeries that are still performed were popularized by McGuire 78 who defined a subgroup of 
patients using urodynamic studies who would benefit most from an autologous sling 
procedure (patients with type 3 SUI (intrinsic sphincter deficiency))79. The introduction of 
urodynamic studies  enabled assessment of the functionality of the lower urinary tract by 
1970s, leading to an increased understanding of urinary incontinence and exploration of its 
potential to improve patient selection for a particular surgical intervention 77.  
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In the 1990s, the integral theory was introduced, forming the basis of the modern tension-
free vaginal tape procedures 80. According to this theory, urethral closure occurs by forward 
contraction of pubococcygeus muscles and backward contraction of levator muscles in the 
presence of an adequate tension in the pubourethral ligament when intra-abdominal 
pressure increases 80. A synthetic mesh placed in the position of the pubourethral ligament 
in a tension-free manner would induce fibrosis and form a collagenous neoligament to 
replace the pubourethral ligament forming a backboard against which the urethra can be 
compressed 81. Furthermore,, the midurethra was shown to be the most critical location to 
place the mesh, instead of the bladder neck, owing to the laxity of the pubourethral 
ligament at this level, which has been observed in urodynamic (urethral pressure profile) 
studies 44. Importantly, the midurethra was validated as a target by measuring the 
improvements in urethral closure pressures preoperatively and postoperatively 44. Thus, the 
pubourethral ligament was accepted as the target tissue replaced by mesh in synthetic 
midurethral sling surgeries. The pubourethral ligament descends like a hammock from the 
inferior part of the pubic bone towards the urethra and vagina (Figure 3c). Biomechanically, 
the pubourethral ligament consists of collagen, elastin, smooth muscle, nerves and blood 
vessels actively and passively suspending the urethra 82. Although mechanical testing of the 
pubourethral ligament was never performed, the proximal part was defined as a fibrous, 
pearly white tissue that is resistant to stretching 83 which histologically consists of dense, 
parallel bundles of collagen fibres directed longitudinally 84. This structural organization can 
be hypothesized to translate into a function that is stronger in one direction rather than a 
predominantly elastic one. Thus, the mesh implanted to replace pubourethral ligament 
would work mostly under unidirectional forces not needing substantial elasticity (Figure 3c).  
[H2] The use of mesh for POP 
Current surgical treatments for POP are based on identification and repair of anatomical 
defects that broadly occur at three levels in the pelvis: level I, the cardinal (Figure 3a) -
uterosacral ligaments (that provide apical support); level II arcus tendinous fascia pelvis (that 
supports the middle part of vagina laterally); and level III, the urogenital diaphragm and 
perineal body (that supports lower part of the vagina) 85. This anatomical description 
provides the basis of pelvic floor support structures that guides the reconstructive surgeon. 
After the level of the defect is identified it can be repaired by either an abdominal or a 
vaginal approach (Figure 3b-d).  
Considering the biomechanical environment of the female pelvic floor when treating POP is 
also important; however, this factor is relatively poorly understood compared to its 
anatomy. Biomechanically, the pelvic floor is known to be composed of active and passive 
soft tissue components attached to the pelvic bones. Passive components, mainly the fascia, 
are unable to generate force but can resist when force is applied to them. The active 
components are the muscles, such as levator ani and the sphincters, which can contract and 
independently generate force 86. How these structures each contribute to the generation of 
the biomechanical environment of the pelvic floor is not completely understood, particularly 
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as they relate to the occurrence and treatment of SUI and POP 87. Nevertheless, some 
deductions can be made with regards to the biomechanical forces acting on the mesh when 
implanted for surgical treatment of SUI and POP. 
Abdominal sacrocolpopexy operations using surgical mesh have been performed since the 
1960s (Figure 3b) 88. In these operations, the mesh material is used to attach the apex of the 
vagina (and the uterus in patients who did not undergo a hysterectomy) to the sacrum 
replacing a defective cardinal- uterosacral ligament complex 88. This ligament complex is 
composed of thick and strong collagenous fibres extending vertically and posteriorly towards 
the sacrum (figure 3a) meaning that it is not necessarily flexible but strong in the vertical 
direction 89. The mesh in these operations is secured in a relatively fixed position in the 
retroperitoneum and would be expected to be loaded mainly by  a unidimensional vertical 
force.  
The forces that act on the mesh are not well defined in transvaginal mesh-augmented POP 
repair procedures. Understanding these forces is complex as the visceral pelvic fascia 
consists of both passive and active soft tissue components, such as muscle fibre s that can 
generate force and fascia that cannot generate force but provide structural support 90. 
Additionally, transvaginal repairs are essentially mesh onlay repairs (Figure 3d), particularly 
anterior and posterior colporraphy procedures, which makes them prone to colonization by 
vaginal microbial flora as they lie very close to the skin  91. This phenomenon is well-known 
in abdominal hernia repairs, in which the chances of mesh colonization and infection is 
increased with onlay mesh hernia repairs (in which the mesh is implanted on top of the 
fascia defect in very close proximity to skin). 35 (figure 2c). Furthermore, with transvaginal 
mesh implants, meshes are probably not placed on a well-vascularized wound bed in most 
patients as many of these patients are postmenopausal and already have poorly 
oestrogenised, less vascularized tissues  92. Thus, in abdominal sacrocolpopexies the mesh 
mostly replaces a passive soft tissue component and the mechanical properties of the mesh 
can probably better match with the requirements at the site of implantation. In contrast, the   
in vivo loading conditions for the mesh are largely unpredictable in transvaginal POP repair 
procedures, where the mesh probably is loaded under multidimensional forces and many 
meshes cope poorly with these mechanical demands 93.  
Considering all these together, it could be suggested that both  the factors related to surgical 
technique and the mechanical mismatch between the mesh and the pelvic floor tissues 
could have contributed to the complication rates observed with these surgeries (Table 1). 
The main problem with the surgical technique when performing  vaginal mesh implantations 
appears to be the insertion of the mesh through a vaginal skin incision where the mesh lies 
in a tissue plane where it is too close to the vaginal skin. The biomechanical problem is that 
of a combination of a mismatch between the mechanical properties of the mesh material 
and the biomechanical requirements of the female pelvic floor, the latter is poorly defined.    
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[H1] Mechanisms of mesh-related complications  
Complications caused by vaginal mesh occur as a result of a combination of several factors, 
including problems related to the mesh material itself, incomplete understanding of disease 
processes leading to SUI and POP, limitations of the surgical techniques used in the 
treatment of SUI and POP, failure of regulatory processes for approval and of surveillance of 
implantable medical devices for this application, factors related to the surgeon and factors 
related to the patient (Boxes 1 and 2) 65.  
[H2] Factors related to the mesh material  
The development of the surgical mesh from metal implants to the modern polymer-based 
meshes shows that the material properties are the main determinants of the surgical 
outcomes with mesh repairs.  
  
[H3] Biocompatibility 
Biocompatibility is  “the ability of a material to perform with an appropriate host response in 
a specific application ” 94. In other words, the material should be able to exert its desired 
function without an unacceptable degree of harm to the host. A host response is expected 
to any synthetic implant and a mutually acceptable coexistence of materials and tissues is 
required. Materials and tissues can interact in many different ways and research on the 
mechanisms of these interactions and their associations with clinical outcomes is still 
ongoing.  
For PPL mesh, the host response has been mainly studied in the context of hernia surgery. 
PPL mesh has been repeatedly shown to trigger a macrophage polarization towards an 
undesirable increased M1:M2 ratio early in the inflammation process 95. A classical M1 
macrophage response is characterized by a proinflammatory state, whereas an M2 response 
is a constructive remodelling response 96. The M1:M2 ratio is increased with high-weight 
meshes with small pores than with light-weight meshes with larger pores 97. Thus, the 
amount of mesh (the mesh burden) in contact with tissue could be a determinant of its 
biocompatibility 98.  
Experimental studies to characterize the inflammatory response to PPL when implanted 
transvaginally started in 2007 in sheep 99. These experiments clearly showed that graft-
related complications (exposure and contraction) occurred considerably more when the 
mesh was implanted in the vagina than in the abdominal wall, with mesh exposure occurring 
in 3 of 10 implanted meshes  100. Thus, the host response to PPL mesh is site specific. In a 
study of women who underwent mesh excision after midurethral sling and prolapse mesh 
implantation, the excised mesh ?vagina complexes were examined to define the type of the 
inflammatory response 101. Women with mesh complications had a proinflammatory (M1) 
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macrophage response years after the implantation. Additionally, in explants of women who 
had mesh exposure, expression of proteolytic enzymes such as matrix metalloproteinase 9 
was increased compared with explants of women who had pain 101. 
 The most important factor that affects the biocompatibility of the mesh is its porosity and 
pore size 24. Light-weight meshes with large pores seem to have the best outcomes, 
especially when used in surgical treatment of POP 102. However, as meshes became lighter 
with increased pore sizes their flexibility also increased. Increased flexibility resulted in a 
change in the overall mesh geometry, causing loss of pores after mechanical loading of the 
mesh at the site of implantation 103. Thus, the concepts of pore stability and effective 
porosity were introduced 104. These factors have become particularly important for POP 
meshes as these meshes are more likely to undergo tensile forces in vivo than hernia 
meshes. Most of the commonly used prolapse meshes have a considerably  reduced porosity 
after uniaxial loading 105,106, meaning that the porosity of the meshes are effectively lost 
after implantation  There have also been studies on improving the mesh design by using 
auxetic geometries, unlike most materials that would become narrower with longitudinal 
stretch auxetic materials expand laterally when they are stretched in a longitudinal direction, 
for prolapse meshes that can avoid pore collapse after implantation in vivo 107. The auxetic 
design allows maintenance of the porosity of the mesh when it is loaded leading to a better 
host response. This could be a strategy to improve the biocompatibility of the meshes; 
however, the ability of these materials to reduce graft related complications, such as mesh 
exposure, contraction and pain, has not yet been demonstrated.   
Changes to the chemical structure of mesh in vivo is another factor that affects 
biocompatibility. Traditionally, PPL mesh was considered not to undergo any physical 
changes after being implanted into human body; however, current evidence suggests that 
the surface of the mesh can crack  108. Out of 164 meshes explanted to treat complications, 
162 demonstrated polymer degradation and superficial inflammatory cells trapped within 
these cracks 108. The biochemical environment of the human body is an aggressive medium 
for mesh materials with a set temperature (37° C), oxygen level (approximatelt 20%), pH (7.4 
in blood) and salt concentration (0.9% NaCl) 109. This environment can cause PPL degradation 
by oxidation 110. Furthermore, degradation can be considerably facilitated by the presence of 
static or cyclic mechanical forces 111. Theoretically, a focal site of surface cracking, abrasion 
or wear can induce generation of macroradicals (a macromolecule that can act as a free 
radical), such as peroxide macroradicals originating from chain rupture leading to increased 
brittleness and deterioration in strength. In conclusion, PPL mesh is resistant to hydrolytic 
(bulk) degradation (which is breaking of chemical bonds in the hydrophilic groups at the 
polymer backbone to form oligomers and monomers) 112, but growing evidence suggests 
that it can undergo considerable chemical and mechanical changes in the human body.  
 
 
[H3] Mechanical failure 
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Plastics have unique mechanical properties that are time dependent, often nonlinear and 
these affect their performance in the long term 113. When a controlled force (stress) is 
applied to a plastic, it causes a change in its size (strain), which is initially proportionate to 
the force applied (linear elasticity) 114. This proportionality is lost at some point during 
loading  and the stress ?strain curve becomes nonlinear and the material starts to deform 
irreversibly, whereas it remains elastic when the curve is linear 114 (Figure 5).  
The mechanical properties of the PPL mesh are a function of the raw material and its textile 
characteristics 93. These properties have mainly been defined under uniaxial tensile testing 
115. This test gives the maximum strength and strainability of the material before it fails. 
Loads above the failure point can also considerably change the material and textile 
properties of the mesh when repeated overtime 116. An in vitro study evaluating the dynamic 
creep behaviour of four  commercially available PPL meshes with different pore size, bulk 
density and  geometries under physiological conditions showed that all meshes underwent 
strain hardening and plastic deformation after cyclic uniaxial loading 117. Strain hardening is 
strengthening of the material during loading when they are stretched above their yield 
point. Data from another study showed that 3 days of fatigue testing in culture conditions 
was enough to demonstrate strain hardening and subsequent failure of some meshes 93. 
Strain hardening is a well-defined phenomenon  for thermoplastics 116  that are used in 
engineering and, from an engineering perspective, cyclic and fatigue tests would be 
expected to be performed to evaluate the deformation of the mesh. Although fatigue tests 
have been widely used for other biomedical implants (such as heart valves and stents) they 
have not been used, to the best of our knowledge, to evaluate vaginal meshes as they were 
considered low-risk medical implants.  
 
 Biomedical implants are normally designed to match the biomechanical environment of the 
implantation site. Biomechanics is an interdisciplinary area of research that involves the 
study of how the forces acting on structural elements of the human body create the motion 
that leads to normal development and functioning or to tissue damage under overloaded 
conditions 118. The biomechanics of the female pelvic floor is a developing area of interest 
and limited knowledge of it is one of the factors that precludes definition of treatment 
targets and, therefore, the design requirements for prosthetic materials 119. Current 
knowledge of the mechanical characteristics of the female pelvic floor is based on 
mechanical testing of whole pelvic floor samples from small animals (such as vaginal 
supportive tissue complex described in rats for experimental purposes  ) 120,121 or biopsies 
from humans  122. These studies showed that the mechanical characteristics of healthy 
vaginal tissue in women has an ultimate tensile strength of 0.79±0.05 MPa, a maximum 
elongation of 1.68±0.11 mm and an elastic modulus of 6.65±1.48 MPa . Computational 
models of the female pelvic floor have the potential to reliably define normal biomechanical 
behaviour and can predict the biomechanical mechanisms leading to damage to pelvic floor 
structures (for example, birth trauma) and pelvic floor disorders 86. Ideally measurements 
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made on specific groups of patients in vivo would be used to characterize the mechanical 
properties of the pelvic floor. Up to now anatomical models demonstrating detailed 3D 
anatomy of the pelvic floor have reliably been produced thanks to magnetic resonance 
imaging 123. Additionally wearable devices that are temporarily implanted into woman 
vagina have been developed to obtain real time measurements of the pressures acting on 
the vaginal  tissues 124.  The remaining challenge seems to be integrating the functionality of 
the muscles and other soft tissues   into these models.  What is really needed is computer 
based models where anatomical, mechanical and biochemical data pertinent to pelvic floor 
muscles and soft tissues can be  combined mathematically. Once an accurate biomechanical 
model is created, population based data can be applied onto these model before they are 
used clinically to predict individual patient/ disease outcomes. 
The mechanical properties of the mesh product can also have an effect on its 
biocompatibility; however this influence is much less studied than  other biomedical 
implants such as hip prostheses. When an implant material is too strong and too stiff for the 
host tissues, a phenomenon called stress shielding can occur in the adjacent tissues leading 
to defective extracellular matrix production 125. This concept is well-defined for bone 
implants and has also been studied in pelvic floor. A study in rhesus macaques showed that 
meshes with increased stiffness caused thinning of the smooth muscle layer, decreased 
vaginal contractility, decreased collagen and elastin content and increased total collagenase 
activity in the vaginal tissues adjacent to implanted mesh 125,126. Thus, the vaginal mesh is 
too strong for the site of implantation and this can lead to deterioration in the strength of 
tissues around the mesh. 
Deformation of the mesh under cyclic distension in the pelvic floor could possibly have 
contributed to the occurrence of mesh-related complications, but demonstrating this direct 
association in vivo would be difficult.  
[H2] Surgical technique 
In vaginal mesh implantations, the mesh stays in very close proximity to the vaginal mucosa 
as no natural tissue planes are present in this region (such as subcutaneous or muscle tissue 
layers) unlike in the abdominal implantations in which the mesh material is implanted in 
between clearly identifiable fat, muscle and fascia tissue planes 127 (Fig 2c-d).  
Several observations suggest that mesh-related complications can result from limitations of 
surgical techniques used for mesh implantation, particularly for POP treatment. First, vaginal 
mesh complications are known to increase when a larger area of the mesh is used 65,100, for 
instance more complications occur with prolapse meshes compared to mesh slings. Second, 
some clinical studies demonstrate that avoiding a vaginal incision suture line being in direct 
contact with the mesh material  could decrease mesh exposure 128,129.  Additionally, avoiding 
a vaginal incision  when implanting a natural scaffold derived from natural extracellular 
matrix on the vaginal wall of rhesus macaques, in these cases the material was implanted 
transabdominally rather than through a vaginal incision,was also shown to eliminate the 
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negative effects on overall structure and function of the vagina with increased vaginal 
stiffness, collagen content and an increased collagen I/ III ratio at 3 months 130. Finally, 
vaginal mesh extrusion described as vaginal mesh being visualized through the separated 
vaginal epithelium most commonly occurs in the midline where the surgical incision is made 
131. Taken together, these observations imply that mesh erosion can be an abnormal wound 
healing response of the incised vaginal mucosa in which a poorly vascularized wound bed 
combined with the surgical intervention and the presence of large amount of mesh material 
leads to poor wound healing. 
 
[H1] Designing improved materials  
  Owing to the aforementioned factors, efforts are being made to improve mesh materials 
for use in pelvic floor reconstruction. The first approach to designing improved materials to 
support the pelvic floor is to develop the existing PPL meshes. The new generation of light-
weight, macroporous meshes with high porosities are associated with reduced fibrosis, pain 
and mesh erosion 132. The knit pattern and geometry of the mesh can also be modified to 
obtain the desired mechanical properties and a more stable effective porosity that function 
well under bilateral dynamic distension 133. To enhance the biocompatibility of PPL, a 
bioactive coating of biocompatible substances (such as natural extracellular matrix 95 or 
titanium 134) can be applied. The usefulness of bioactive coating in improving the 
biocompatibility of the meshes although has been assessed in pre-clinical studies still needs 
to be evaluated further in clinical studies.  
Advances in materials science and tissue engineering are now being applied to designing 
novel materials specifically for use in the pelvic floor. The first tissue-engineering approach 
to construct an autologous fascia equivalent for POP repair was reported in 2010 135. In this 
study, human vaginal fibroblasts were seeded on a PLGA (poly(lactic-co-glycolic acid) knitted 
mesh before implantation into nude mice for 12 weeks and formation of a well-organized 
new fascia-like tissue was demonstrated 135. PLGA-based materials may fail to provide 
durable structural support, a stronger tissue-engineered material was also constructed from 
knitted silk mesh seeded with adipose-derived mesenchymal stem cells (MSCs) in 2013 136. 
This material was not tested for their efficacy in relevant animal models. Including cellular 
components or naturally derived matrix proteins in mesh materials have been evaluated as a 
strategy to improve the biocompatibility of the materials. In 2013, novel synthetic materials 
such as polyether ether ketone and polyamide as alternative materials to PPL were 
evaluated in comparative studies 137. A polyamide knitted mesh coated in gelatine and 
seeded with endometrial MSCs that was designed for POP repair was shown to reduce 
inflammatory cell infiltration and increase neovascularization in a rat model in 2013 138.  
 Materials can also be fabricated using alternative methods. For example, electrospinning 
produces microsized or nanosized fibres with different compositions and configurations that 
can mimic the organization of natural extracellular matrix. Electrospinning can create 
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transversely, obliquely and irregularly aligned fibres consisting of poly-L-lactic acid (PLA) in a 
trilayer structure with biomechanical properties similar to native fascia 139. Host immune 
response to these layered PLA scaffolds was characterized as a predominantly M2 
(remodelling) type of immune response 30 and 90 days after implantation onto the 
abdomen of a cohort of rabbits  140. Considering a range of degradable and nondegradable 
materials, such as PLA and a polymer of polyurethane, respectively, is important as different 
applications in the pelvic floor might require different material characteristics. For example, 
a relatively strong and degradable mesh material would be required for treatment of uterine 
or vault prolapse, whereas degradable materials that are not necessarily as strong would be 
better suited for low-grade prolapse in anterior or posterior vaginal compartments. PLA is 
known to have good biocompatibility and is commonly used in drug delivery applications 141. 
Another promising material is polyurethane which has increased elasticity that can 
withstand cyclic mechanical distension in vitro 142. Electrospun polyurethanes and  
electrospun ureidopyrimidinone-polycarbonate scaffolds, led to a better host response with 
an M2 type predominant (remodelling response) inflammatory response  than 
ultralightweight PPL meshes after implantation into sheep vagina for 6 months  143. 
Electrospun materials and ultralightweight PPL were similar with regards to graft-related 
complications, passive mechanical properties and their effects on vaginal contractility 143. 
These suggest that materials with increased elasticity can be promising candidate materials 
for use in pelvic floor reconstruction. 
Another desirable property of these biomaterials is, arguably, their ability to stimulate new 
blood vessel formation at the site of implantation. This stimulation could result in an 
improved wound healing, which is  particularly important in circumstances in which the 
wound bed is already poorly vascularized, such as the pelvic floor tissues of postmenopausal 
women with SUI and POP 92. Polymers can be combined with bioactive factors such as 
ascorbic acid 144 and estradiol 145,146 to stimulate neovascularisation and new extra cellular 
matrix production without having an adverse effect on mechanical properties of these 
materials144-140. These materials are yet to be tested in appropriate animal models, such as 
the sheep vagina in which the failure of some existing materials can be  demonstrated 100.  
From a regulatory perspective, novel products to be used in pelvic reconstructive surgeries 
should be subject to regulations for advanced therapy medicinal products if they involve a 
gene and/or cell therapy component or it is a tissue engineered product. These products 
should also be subject to regulations for medical devices if the biomaterial is composed only 
of a material (not involving a cellular products). Nevertheless, the regulations for any 
implantable medical devices are increasingly being criticized and clinical trials should be 
mandatory before any new devices are approved, especially for those used in pelvic floor 
surgery. Establishing registries for monitoring adverse outcomes is also required.  
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[H1] Conclusions 
Surgical mesh has evolved over many years from an initial metal wire mesh to the 
monofilament, macroporous PPL mesh used in contemporary practice. The developments 
made to the material were a result of clinical feedback, mostly in the context of hernia 
repair, over a considerable period of time. Surgical techniques of implantation were also 
modified to make use of the newly available material to obtain best surgical outcomes for 
patients. As a result, mesh-augmented surgical repairs now have reasonable success rates  in 
abdominal hernia surgeries, in which they resulted a considerable reduction in hernia 
recurrence after repair surgeries. However, hindsight shows that the assumption that 
materials that work well in hernia repair would work equally well when used in the pelvic 
floor was naive. At the time of making this assumption, knowledge of the forces that the 
materials experience in the pelvic floor was poor and the available regulatory processes did 
not require either efficacy data from in vivo studies or clinical data before these devices 
were approved for clinical use in women. As a result, the vaginal mesh has both 
mechanically and biologically failed when used in pelvic floor. The scientific and surgical 
communities now have clear evidence that an implant material needs to be designed and 
tested for a particular clinical applications using relevant animal models, which will then 
inform the legal decision makers on the necessity of clinical trials before approval and 
postmarket surveillance.  
Mesh materials to be implanted in the vagina have now been upgraded to a category III 
regulatory risk. In the future, any new materials to be evaluated will need to undergo much 
more rigorous evaluation in appropriate animal models and also clinical safety studies.  
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Figure 1. Milestones in development of the polypropylene mesh as a material used in pelvic floor 
repair. In hernia surgery, mesh material evolved over many years from a metal wire to a lightweight 
plastic mesh made of polypropylene (PPL). In parallel to the modifications in material properties of 
the mesh, the surgical technique of mesh positioning was also modified. In pelvic floor 
reconstruction, the materials were adopted for use in the pelvic floor after they were first used in 
hernia repair. Synthetic mesh was first approved for use in stress urinary incontinence (SUI), then for 
pelvic organ prolapse (POP). The anatomical and functional basis of SUI seems to have been well-
studied before mesh was introduced, whereas for POP, the structural pathophysiology was described 
by DeLancey 85 only a decade ago. (*only mesh augmented incisional hernia repair procedures as 
they are related to mesh positioning are included here). 18, 19, 22, 23, 24, 39, 40, 41, 42, 44, 73, 77, 79, 80, 147 148 149 150 
151 152 153 154 155 156  
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Figure 2. Mesh positioning in relation to muscle and fascia in incisional hernia repair. (A) A cross-
section of anterior abdominal wall with a fascia defect causing herniation of the intestine. (B) Inlay 
mesh implantation to fit in the gap created by the fascia defect. This method was largely abandoned 
owing to high recurrence rates. (C) Onlay placement of mesh material to overlie and reinforce the 
fascia repair. (D) In the sublay technique, the mesh is placed on a well-vascularized wound bed 
underneath the muscle and is in between two strong fascial layers. This technique is considered the 
current gold standard and is associated with reduced complication and high success rates. (E) The 
underlay technique started to be used after widespread use of laparoscopic surgery. In this method, 
a mesh with antiadhesive properties would be preferable to a polypropylene mesh to prevent 
attachment of intra-abdominal organs.  
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Figure 3. The most common sites of surgical mesh implantation in the pelvic floor. (A) Anatomical 
features commonly involved in pelvic floor surgery: pelvic floor muscles and uterosacral ligament 
(level I support),  sacrospinous ligament and arcus tendinous fascia pelvis (ATFP) (level II support). 
The rectum is not included and the uterus is removed when necessary to obtain improve visibility. (B) 
Transabdominal placement of polypropylene (PPL) mesh to treat pelvic organ prolapse (POP) 
(sacrocolpopexy operations). In these operations, the mesh is secured in a fixed position and mainly 
experiences a unidimensional downward force. (C) Transvaginal implantation of PPL mesh at the 
level of the midurethra to treat stress urinary incontinence (SUI). Here, a retropubic midurethral sling 
is depicted. (D) Transvaginal placement of PPL mesh for POP repair, 45° lateral view and 30° 
anterosuperior view. Many variations of these operations exist; here, the tissue plane in which the 
mesh is implanted in mesh-augmented anterior colporraphy procedures (upper image) and how the 
mesh kits be can be used to fix the mesh to the sacrospinous ligament and/or the ATFP are shown. In 
both cases, multi-axial forces are acting on the mesh and a large area of the mesh stays in close 
proximity to vaginal skin, making it prone to bacterial colonization. These factors all might have 
contributed to occurrence of mesh related complications.  
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Figure 4. The industrial process used to produce monofilament polypropylene (PPL) mesh compared 
with a tissue engineering process called electrospinning. (A) Polymer extrusion process to produce 
the monofilament PPL mesh. (B) The end product of extrusion process gross view, (C) electron 
microscopic view and (D) the resultant tissue response to the PPL. (E) Electrospinning of another 
polymer to produce (F) an electrospun mat with (G) microsized and nanosized fibres with micropores 
in electronmicroscopic view. (H) Tissue sections of the electrospun mesh show excellent tissue 
infiltration. (*the mesh in tissue sections). 
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Figure 5. The basic mechanical properties of a material determined by uniaxial mechanical testing. 
The tensiometer setup is demonstrated in part (A). The load-elongation curve produced by this test is 
demonstrated in (B) with the change in appearance of the sample loaded to the tensiometer (C). The 
maximum load is the maximum amount of stress that a material can bear before it fails. The 
maximum elongation is the maximum strain a material can achieve before it fails. In region I, the 
material goes back to its exact size and shape after the load is removed. After the yield point (region 
II) plastic deformation starts and the material does not go back to its original state after the load is 
removed, although an obvious change in the material might not be observed. Towards the end of this 
region, necking of the material starts which reflects permanent deformation. Soon after the 
maximum load is applied the material completely fails and a fracture line can be observed. The 
regions are marked for graphical clarity, they do not necessarily depict the real distribution of the 
regions according to material elongation.  
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Box 1. Problems in mesh development for pelvic floor repair  
1. Lack of appropriate regulations for approval of medical devices  
a. Devices granted approval with no or limited clinical data 
2. Lack of understanding of female pelvic floor disorders 
a. Structural and functional complexity of female pelvic floor unclear  
b. Pelvic floor biomechanics not well studied 
c. Targets for surgical treatment generally poorly defined, particularly in transvaginal pelvic 
organ prolapse repairs 
3. Problems related to the material  
a. Surgical mesh not designed for use in pelvic floor 
b. Limitations in available material processing technologies  and materials at the time 
c. Polypropylene considered inert; however, surface degradation occurs  
4. Factors related to surgical technique 
a. Proximity of large areas of mesh implant to mucosal wound  
b. Implantation of mesh onto a poorly vascularized wound bed 
5. Lack of relevant animal models of efficacy and safety  
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Box 2. Problems following widespread clinical use of the mesh for SUI and POP. 
1. Lack of post marketing surveillance  
2. Poor patient selection 
a. Poorly defined disease subgroups  
b. One-size-fits-all approach 
3. Factors related to operating surgeon 
a. Poor subspecialty training on management of all aspects of stress urinary incontinence and 
pelvic organ prolapse 
b. Minimally invasive operations perceived as easy to perform  
4. Extensive marketing  
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Table 1. Mesh success and complication rates in incisional hernia repair and the pelvic floor.  
Surgery  Composition of 
the proposed 
target tissue 
Mechanical 
loading of the 
mesh at the site 
of implantation 
Success rate* 
(follow-up 
duration) 
Serious mesh-
related 
complications 
Abdominal (incisional) 
hernia repair 
Fascia  Biaxial 86.8- 88.8% 
(5 years)  
 
4.5%  
(5 years)  
SUI 
(Mid-urethral sling) 
Mostly fascia  Uniaxial 43- 93% 
(>5 years)  
4% 
(5 years)  
 
Abdominal POP repair 
(sacrocolpo(hystero)pexy) 
Fascia Uniaxial 93-95% 
(7 years)  
6-10%  
(7 years)  
 
Transvaginal POP repair 
(Vaginal colpo 
(hystero)pexy; Anterior 
and colporrhaphies) 
Fascia plus 
smooth muscle 
plus ECM (poorly 
defined) 
Biaxial and/or 
multiaxial? 
(poorly defined) 
53- 82%  
(7 years) 
Up to 42%  
(7 years)  
 
 
 Comparisons were made related to the definition of the target tissue that is being replaced in these 
surgeries and the loading conditions of the mesh at the site of implantation. (*definition of success is 
not standard please check the references for further information)  
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Table 2. Comparison of polymer processing methods of extrusion and electrospinning. 
Component or process Extruded mesh Electrospun mesh 
Raw material Polymer beads Polymer beads 
Additives Yes No 
Liquifying process Heating Dissolving 
Manufacturing principle Extrusion Electrical field 
Post process Knitting None 
Sterilization Autoclave Good Manufacturing Practice 
Pore size >70 micrometers  1-10 µm 
Fibre size 300-500 µm 1-10 µm 
Tissue integration Poor Excellent 
Level of technology Industrialized process Tissue engineering process 
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